$ABT

Abbott has launched Similac 360 Total Care Made With Whole Milk, a ready-to-feed liquid infant formula. The product is made with whole milk and is designed to support immune health, brain development, and digestive health. Abbott is offering the formula in 8- and 32-fluid-ounce formats, with pricing comparable to its powdered formula. The product is initially available through Target and Amazon, with wider retail distribution expected soon. According to Abbott, the formula addresses consumer dem

Abbott Nutrition agreed to pay $670 million to resolve claims related to its preterm infant formulas, without admitting liability. The settlement includes a Missouri case where a jury awarded $495 million to a plaintiff. Abbott maintains its products are safe and supported by medical professionals. Separately, Abbott challenged competitor Kendamil's advertising claims, with NAD recommending Kendamil remove certain claims about nutritional benefits.

The FDA approved Abbott Laboratories' Libre Duo 10 Day, a wearable device that continuously monitors both glucose and ketone levels. This first-of-its-kind tracker aims to prevent life-threatening emergencies like diabetic ketoacidosis (DKA) by providing real-time data. Abbott claims the device simplifies monitoring for diabetes patients, who previously had to use separate tests for ketones.

Four healthcare stocks—JNJ, ABT, MDT, and BDX—raised dividends through two recessions. JNJ (JNJ, $266.60, 1.97% yield) has a 64-year streak and $21B FCF. MDT (MDT, $90.83, 3.16% yield) leads in yield with 49 years of raises. ABT (ABT, $110.10, 2.22% yield) has 54 years of raises. BDX (BDX, $188.67, 2.23% yield) grew FCF 45% YTD. All benefit from inelastic demand for healthcare products.

Abbott Laboratories (ABT) received FDA approval for its Libre Duo 10 Day sensor, which tracks glucose and ketone levels. The company's stock closed at $112.47, with mixed returns over different periods. Analysts suggest ABT is 5.6% undervalued, with a fair value of $119.13, citing innovation in high-margin segments. However, investors should monitor diagnostic pricing in China and potential litigation risks.

Abbott Laboratories (ABT) disclosed a cyber incident where 10.9M email addresses and personal health data were leaked by ShinyHunters after a vishing attack. The breach, tied to its Cancer Diagnostics business, did not impact other operations. Abbott refused to pay ransom, leading to the data dump. The incident highlights the rise of vishing attacks in cybercrime.

Alpha Compute (ALP), Abbott Laboratories (ABT), and HUB Cyber Security (HUBC) hit 52-week lows. ALP fell 11% after rebranding, ABT dropped 3% due to acquisition costs, and HUBC tumbled 54% after a reverse stock split. Daiwa downgraded ABT to 'Neutral' with a $92 price target.

The Trump administration may add two FDA deputy commissioner roles. FDA approved first-of-kind treatments from Revolution Medicines (Rasonque for pancreatic cancer), Priovant Therapeutics (Lisraya for dermatomyositis), and Janssen Biotech (Imaavy for wAIHA). Abbott's Libre Duo 10 Day received de novo authorization for a dual glucose and ketone monitoring system. FDA issued alerts for Abiomed, Medtronic, and Boston Scientific devices, and recalls for Boston Scientific and AVID Medical products.

Abbott Laboratories (ABT) received FDA authorization for its Libre Duo 10 Day system, a wearable that monitors glucose and ketone levels. The U.S. launch is planned for later this year. Abbott projects $60.4 billion revenue and $9.5 billion earnings by 2029. The company faces litigation and other challenges, but the new device could strengthen its diabetes platform. Analysts' fair value estimates for ABT shares range from $119 to $152.

Abbott (ABT) fell 2.2% to $111.59, underperforming major indices. Over the past month, its shares rose 5.65%, lagging the medical sector but outperforming the S&P 500. Analysts expect Q2 EPS of $1.43 (10% YoY growth) and revenue of $12.91B (13.52% YoY growth). Full-year estimates project EPS of $5.52 and revenue of $50.18B, up 7.18% and 13.19% YoY, respectively. ABT has a Zacks Rank of #3 (Hold) and trades at a Forward P/E of 20.66.